H. Hirte

H. Hirte, H. Hirte, F. Moens, 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Hypercalcemia of Malignancy

H. Hirte, T. Carling, G. Hendy, 2002 .

A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)

D. Cescon, Helen X. Chen, H. Hirte, 2015, Investigational New Drugs.

A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer

M. Gleave, E. Eisenhauer, H. Hirte, 2008, Clinical Cancer Research.

Malignant ascites fluid (MAF), including ovarian-cancer-associated MAF, contains angiostatin and other factor(s) which inhibit angiogenesis.

H. Hirte, M. Richardson, M. Hatton, 2002, Gynecologic oncology.

Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer

H. Hirte, L. Elit, 2002, Current opinion in obstetrics & gynecology.

Establishment and characterization of four human epithelial ovarian carcinoma cell lines

H. Hirte, S. Bacchetti, Jutta Kaiser, 1994, Cancer.

Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline

H. Hirte, L. Elit, X. Yao, 2022, Current oncology.

An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma

H. Hirte, L. Elit, X. Yao, 2021, Current oncology.

A phase II trial of JM-216 in cervical cancer: an NCIC CTG study.

L. Seymour, H. Hirte, D. Lebwohl, 2002, Gynecologic oncology.

Study Design Solutions for Adjuvant and Maintenance Therapy in Cancer: Ovarian Cancer as an Example

H. Hirte, Jinhui Ma, L. Elit, 2022, SN Comprehensive Clinical Medicine.

Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: Identification of transforming growth factor-β as a suppressive factor

H. Hirte, D. Clark, 2005, Cancer Immunology, Immunotherapy.

Decidua-associated suppressor cells in abortion-prone DBA/2-mated CBA/J mice that release bioactive transforming growth factor beta2-related immunosuppressive molecules express a bone marrow-derived natural suppressor cell marker and gamma delta T-cell receptor.

H. Hirte, P. Arck, D. Hoskin, 1997, Biology of reproduction.

A Subset of Patients With Recurrent Spontaneous Abortion Is Deficient in Transforming Growth Factor β‐2‐Producing “Suppressor Cells” in Uterine Tissue Near the Placental Attachment Site

C. Harley, K. Flanders, H. Hirte, 1995, American journal of reproductive immunology.

Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab

A. Oza, D. Gandara, H. Hirte, 2008, Clinical Cancer Research.

Novel Transforming Growth Factor Betas (TGFβ2) in Pregnancy and Cancer

K. Flanders, H. Hirte, J. Mowbray, 1994 .

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)

A. Oza, H. Hirte, S. Kamel‐Reid, 2012, British Journal of Cancer.

Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial

G. Jayson, H. Hirte, S. Kaye, 2013 .

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.

Jeffrey W. Clark, H. Hirte, H. Lenz, 2007, The oncologist.

A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial

A. Oza, H. Hirte, Lisa I. Wang, 2008 .

Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.

W. M. Smit, A. Oza, H. Hirte, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review

A. Oza, H. Hirte, T. Oliver, 2006, International Journal of Gynecologic Cancer.

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.

D. Provencher, H. Hirte, I. Vergote, 2012, The Lancet. Oncology.

Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG

E. Eisenhauer, R. Kimmig, H. Hirte, 2004 .

E. Eisenhauer, R. Kimmig, H. Hirte, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An international multicentre Phase III study of BAY 12-9566 (BAY) versus placebo in patients (pts) with advanced ovarian cancer (OVCA) responsive to primary surgery/Paclitaxel + Platinum containing chemotherapy (CT)

M. Carey, L. Seymour, H. Hirte, 2001 .

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

G. Pond, A. Oza, D. Birle, 2006, British Journal of Cancer.

Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.

H. Mackay, A. Oza, H. Hirte, 2012 .

A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors

A. Oza, B. Clarke, H. Hirte, 2013, Investigational New Drugs.

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)

A. Oza, B. Clarke, H. Hirte, 2013, Investigational New Drugs.

Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.

G. Pond, A. Oza, J. Dancey, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A Princess Margaret Phase II Consortium Trial

H. Hirte, 2005 .

CD56+ lymphoid cells in human first trimester pregnancy decidua as a source of novel transforming growth factor-beta 2-related immunosuppressive factors.

K. Flanders, H. Hirte, D. Clark, 1994, Human reproduction.

Two Phase I Studies of Carboplatin Dose Escalation in Chemotherapy-Naive Ovarian Cancer Patients Supported With Patients Supported With Granulocyte-Macrophage Colony-Stimulating Factor

E. Eisenhauer, H. Hirte, P. Bryson, 1991 .

Evaluation of DNA Methylation Array for Glioma Tumor Profiling and Description of a Novel Epi-Signature to Distinguish IDH1/IDH2 Mutant and Wild-Type Tumors

H. Hirte, G. Paré, D. Grafodatskaya, 2022, Genes.

An Optimized Clinical Regimen for the Oncolytic Virus PV701

H. Hirte, S. Hotte, M. Roberts, 2007, Clinical Cancer Research.

An Optimized Clinical Regimen for the OncolyticVirus PV 701 Se ¤

H. Hirte, M. Roberts, R. Lorence, 2007 .

Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-beta in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody.

H. Hirte, J. Rusthoven, D. Clark, 1992, Cellular immunology.

Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial.

G. Pond, A. Oza, H. Hirte, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A rapid and simple method for the purification of tumor cells from ascitic fluid of ovarian carcinoma

H. Hirte, J. Rusthoven, D. Clark, 1992, Gynecologic oncology.

EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.

W. Mason, M. J. van den Bent, T. Gorlia, 2022, Journal of Clinical Oncology.

Vascular Endothelial Growth Factor Concentration as a Predictive Marker: Ready for Primetime?

H. Hirte, S. Hotte, P. Kavsak, 2010, Clinical Cancer Research.

Predictive Marker: Ready for Primetime? Vascular Endothelial Growth Factor Concentration as a

H. Hirte, S. Hotte, P. Kavsak, 2010 .

Characterization of Mutational Status, Spheroid Formation, and Drug Response of a New Genomically-Stable Human Ovarian Clear Cell Carcinoma Cell Line, 105C

M. Carey, H. Hirte, H. Itamochi, 2020, Cells.

Novel Targeted Therapies in Ovarian Cancer

H. Hirte, L. Elit, 2014 .

Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.

A. Oza, M. Gore, H. Hirte, 2018, Gynecologic oncology.

The arotinoids: early clinical experience and discussion of future development.

H. Hirte, R. Tozer, B. Kowaleski, 1994, Leukemia.

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

Eilon D. Kirson, Yoram Palti, Steven A. Toms, 2017 .

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.

L. Recht, R. Stupp, M. Weller, 2017, The Lancet. Oncology.

Short‐Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

D. Osoba, J. Menten, W. Mason, 2017, The New England journal of medicine.

UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium.

G. Pond, A. Oza, M. Carey, 2007, Gynecologic oncology.

Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors

J. Blay, Y. Bang, H. Hirte, 2021, Investigational New Drugs.

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

M. Parmar, E. Eisenhauer, J. Ledermann, 2016, The Lancet.

Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap

W. Meschino, H. Hirte, M. Bernardini, 2018, Journal of Medical Genetics.

Induction of hTERT Expression and Telomerase Activity by Estrogens in Human Ovary Epithelium Cells

H. Hirte, G. Fontemaggi, Y. Cong, 2000, Molecular and Cellular Biology.

A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer.

L. Seymour, H. Hirte, M. Moore, 2005, Urologic oncology.

A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors

H. Hirte, S. Hotte, Q. Chu, 2014, Investigational New Drugs.

BAY 43-9006: early clinical data in patients with advanced solid malignancies.

H. Hirte, S. Hotte, 2002, Current pharmaceutical design.

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).

E. Eisenhauer, A. Oza, H. Hirte, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.

H. Mackay, A. Oza, M. Tsao, 2010, European journal of cancer.

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.

S. Groshen, A. Oza, D. Gandara, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.

B. Monk, A. Oza, H. Hirte, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)

D. Matei, A. Oza, M. Tsao, 2020, Clinical Cancer Research.

A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.

H. Mackay, A. Oza, H. Hirte, 2014, Gynecologic oncology.

Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221

A. Tinker, D. Provencher, L. Seymour, 2019, Clinical Cancer Research.

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies

H. Hirte, L. Siu, Diane A van der Biessen, 2019, Targeted Oncology.

Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.

J. Blay, Y. Bang, H. Hirte, 2014 .

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

A. Oza, H. Hirte, L. Siu, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma

H. Hirte, 2013, OncoTargets and therapy.

Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care

Fiona A Miller, Robin Z Hayeems, Stephen Welch, 2013, European Journal of Human Genetics.

Novel developments in angiogenesis cancer therapy

H. Hirte, 2009, Current oncology.

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

D. Matei, A. Oza, D. Provencher, 2019, Clinical Cancer Research.

Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial

Vincent Ferretti, John D McPherson, Ben Tran, 2013, International journal of cancer.

Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma

A. Tinker, H. Mackay, A. Oza, 2017, JAMA oncology.

Study Design Solutions for Adjuvant and Maintenance Therapy in Cancer: Ovarian Cancer as an Example

H. Hirte, Jinhui Ma, L. Elit, 2022, SN Comprehensive Clinical Medicine.

Phase I study of temsirolimus (CCI-779), carboplatin, and paclitaxel in patients (pts) with advanced solid tumors: NCIC CTG IND 179.

E. Eisenhauer, A. Oza, H. Hirte, 2009, Journal of Clinical Oncology.

Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).

J. Fletcher, G. Demetri, R. Herrmann, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA

Donald M. O'Rourke, John H. Sampson, Michael Lim, 2016 .

A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677).

D. Osoba, J. Menten, W. Mason, 2016 .

A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia.

H. Mackay, A. Oza, H. Hirte, 2010 .

Biochip arrays for the discovery of a biomarker surrogate in a phase I/II study assessing a novel anti-metastasis agent.

H. Hirte, D. Wong, S. Hotte, 2009, Clinical biochemistry.

Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification

A. Talhouk, S. Leung, A. Tinker, 2022, Modern Pathology.

A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma.

J. Carmichael, H. Hirte, R. Buckman, 1997, Gynecologic oncology.

Phase I trial of OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): Final results.

M. Gleave, H. Hirte, C. Higano, 2010 .

A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.

H. Mackay, A. Oza, B. Clarke, 2015, Gynecologic oncology.

Expanded CD56superbrightCD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model

H. Hirte, Amanda J. Lee, M. Chew, 2018, Cancer Immunology Research.

Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells

H. Hirte, Amanda J. Lee, F. Vahedi, 2018, Cancer Immunology, Immunotherapy.

Characterization of murine pregnancy decidua transforming growth factor beta. I. Transforming growth factor beta 2-like molecules of unusual molecular size released in bioactive form.

K. Flanders, H. Hirte, G. Laurent, 1995, Biology of reproduction.

in Pregnancy and Cancer

K. Flanders, H. Hirte, J. Mowbray, 1994 .

O3.2Phase I and dose ranging, phase II studies with IPH2201, a humanized monoclonal antibody targeting HLA-E receptor CD94/NKG2A

A. Tinker, L. Seymour, H. Hirte, 2015 .

Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium

A. Oza, H. Hirte, J. Wright, 2010, International Journal of Gynecologic Cancer.

Cytokine elevations in acute coronary syndrome and ovarian cancer: a mechanism for the up-regulation of the acute phase proteins in these different disease etiologies.

H. Hirte, J. Gauldie, P. Kavsak, 2008, Clinical biochemistry.

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

E. Eisenhauer, H. Hirte, A. Razak, 2011, British Journal of Cancer.

Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.

D. Matei, A. Oza, D. Provencher, 2016 .

Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520

H. Hirte, L. Siu, Diane A van der Biessen, 2019, Targeted Oncology.

Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer.

M. Parmar, A. Oza, J. Ledermann, 2017 .

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study.

L. Seymour, M. Brundage, H. Hirte, 2006, Gynecologic oncology.

A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers

H. Mackay, A. Oza, R. Plummer, 2017, Targeted Oncology.

APhase 1 Study of Mapatumumab ( Fully HumanMonoclonal Antibody toTRAIL-R 1 ) in Patients with Advanced Solid Malignancies Se ¤

A. Oza, H. Hirte, L. Siu, 2008 .

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial

M. Parmar, A. Oza, J. Ledermann, 2021, ESMO open.

A pneumococcal pneumonia and influenza vaccination quality improvement program for women receiving chemotherapy for gynecologic cancers at a major tertiary cancer Centre.

H. Hirte, L. Elit, C. Hillis, 2021, Gynecologic oncology.

A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.

A. Oza, H. Hirte, S. Lheureux, 2015, Gynecologic oncology.

A phase 1/2 study of ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia.

A. Tinker, H. Mackay, A. Oza, 2014 .

Dose ranging study of monalizumab (IPH2201) in patients with gynecologic malignancies: A trial of the Canadian Cancer Trials Group (CCTG): IND221

A. Tinker, D. Provencher, L. Seymour, 2016 .

Bullous vesicant-type reaction to docetaxel along the venous tract: A case report

H. Hirte, L. Bernard, Jane Su, 2020, Gynecologic oncology reports.

405 POSTER Final results of a Phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers

H. Hirte, W. Miller, D. Wong, 2007 .

A Phase II Study of Patupilone (EPO906) in Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer

W. M. Smit, A. Oza, H. Hirte, 2012 .

A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCIC CTG IND.154

M. Gleave, H. Hirte, E. Eisenhauer, 2005 .

A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: Final analysis.

H. Hirte, S. Hotte, Q. Chu, 2013 .

A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors.

H. Hirte, C. Sessa, S. Kaye, 2011, Journal of Clinical Oncology.

Association of Phosphorylated Epidermal Growth Factor Receptor with Survival in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Radiotherapy

T. Whelan, H. Hirte, T. Tsakiridis, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination

G. Pond, A. Oza, H. Hirte, 2006, Clinical Cancer Research.

Cervicomedullary hemangioblastoma treated with bevacizumab

H. Hirte, J. Provias, A. Algird, 2020, Neuro-Oncology Advances.

Phase II study of cabozantinib (cabo) in patients (pts) with recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago, and California phase II consortia.

A. Oza, H. Hirte, S. Lheureux, 2017 .

OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against HSP27: Results of a first-in-human trial.

M. Gleave, H. Hirte, C. Higano, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply.

L. Recht, R. Stupp, M. Weller, 2017, The Lancet. Oncology.

CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib—A trial of the PMH Phase II Consortium

A. Oza, H. Hirte, J. Wright, 2007 .